Associated Papers
Systematic artifacts from Illumina two-color chemistry confound variant identification and actionability in clinical panels.
Jin H et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
TRIM24-mediated K27-linked ubiquitination of ULK1 alleviates energy stress-induced autophagy and promote prostate cancer growth in the context of SPOP mutation.
Chen S et al.
Cell Death and Differentiation, 2025
A structurally informed human protein-protein interactome reveals proteome-wide perturbations caused by disease mutations.
Xiong D et al.
Nature Biotechnology, 2025
SPOP and MMR/MSI alterations in prostate cancer: relationship with PD-L1, TILs and AR expression.
Fiorentino V et al.
Pathologica, 2025
Cancer-associated SPOP mutations enlarge nuclear size and facilitate nuclear envelope rupture upon farnesyltransferase inhibitor treatment.
Wang Z et al.
The Journal of Clinical Investigation, 2025
SPOP-dependent destabilization of SYT12 in a GSK-3β-dependent manner in papillary thyroid cancer cells.
Zhou S et al.
Clinical and Experimental Medicine, 2025
The equilibrium between two quaternary assembly states determines the activity of SPOP and its cancer mutants.
Cuneo MJ et al.
Biorxiv : the Preprint Server for Biology, 2025
Reannotation of cancer mutations based on expressed RNA transcripts reveals functional non-coding mutations in melanoma.
Pepe D et al.
American Journal of Human Genetics, 2025
Updates on SPOP Gene Mutations in Prostate Cancer and Computational Insights From TCGA cBioPortal Database.
Zakari S et al.
Scientifica, 2025
ELK3 destabilization by speckle-type POZ protein suppresses prostate cancer progression and docetaxel resistance.
Lee CJ et al.
Cell Death & Disease, 2024
Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project.
Shiota M et al.
Bjc Reports, 2024
Deficiency in SPOP-mediated ubiquitination and degradation of TIAM1 promotes gastric cancer progression.
Liu F et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease, 2024
Reduction of oligomer size modulates the competition between cluster formation and phase separation of the tumor suppressor SPOP.
Sabri N et al.
The Journal of Biological Chemistry, 2023
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression.
Geng C et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Opposing Roles of SPOP Mutations in Human Prostate and Endometrial Cancers.
Cavalcante L et al.
Jco Precision Oncology, 2023
SPOP targets the immune transcription factor IRF1 for proteasomal degradation.
Schwartz I et al.
Elife, 2023
Circulating Tumor DNA Analysis on Metastatic Prostate Cancer with Disease Progression.
Bang S et al.
Cancers, 2023
In-Depth Comparison of Genetic Variants Demonstrates a Close Relationship Between Invasive and Intraductal Components of Prostate Cancer.
Vormittag-Nocito E et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2023
Reduction of oligomer size modulates the competition between cluster formation and phase separation of the tumor suppressor SPOP.
Sabri N et al.
Biorxiv : the Preprint Server for Biology, 2023
Higher-order SPOP assembly reveals a basis for cancer mutant dysregulation.
Cuneo MJ et al.
Molecular Cell, 2023
Identification of T Cell Receptors Targeting a Neoantigen Derived from Recurrently Mutated FGFR3.
Tate T et al.
Cancers, 2023
SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis.
Gao K et al.
Cell Death and Differentiation, 2023
CHD1, a multifaceted epigenetic remodeler in prostate cancer.
Li H et al.
Frontiers in Oncology, 2023
Clinicopathological and molecular analysis of microsatellite instability in prostate cancer: a multi-institutional study in China.
Zhang H et al.
Frontiers in Oncology, 2023
SPOP inhibits BRAF-dependent tumorigenesis through promoting non-degradative ubiquitination of BRAF.
Feng K et al.
Cell & Bioscience, 2022
Whole-exome Sequencing of Nigerian Prostate Tumors from the Prostate Cancer Transatlantic Consortium (CaPTC) Reveals DNA Repair Genes Associated with African Ancestry.
White JA et al.
Cancer Research Communications, 2022
ERK1/2 inhibits Cullin 3/SPOP-mediated PrLZ ubiquitination and degradation to modulate prostate cancer progression.
Fan Y et al.
Cell Death and Differentiation, 2022
Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.
Fontugne J et al.
Jci Insight, 2022
GLI3 Is Stabilized by SPOP Mutations and Promotes Castration Resistance via Functional Cooperation with Androgen Receptor in Prostate Cancer.
Burleson M et al.
Molecular Cancer Research : Mcr, 2022
SPOP promotes CDCA5 degradation to regulate prostate cancer progression via the AKT pathway.
Luo Z et al.
Neoplasia (new York, N.y.), 2021
SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions.
Jiang Q et al.
Molecular Cancer, 2021
Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
Shi L et al.
Cancer Research, 2021
2-kupl: mapping-free variant detection from DNA-seq data of matched samples.
Wang Y et al.
Bmc Bioinformatics, 2021
ATM-phosphorylated SPOP contributes to 53BP1 exclusion from chromatin during DNA replication.
Wang D et al.
Science Advances, 2021
SPOP-PTEN-SUFU axis promotes progression of clear cell renal cell carcinoma via activating SHH and WNT pathway.
Han B et al.
Cell Death Discovery, 2021
Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.
Bernasocchi T et al.
Nature Communications, 2021
A disease-relevant mutation of SPOP highlights functional significance of ATM-mediated DNA damage response.
Xiao M et al.
Signal Transduction and Targeted Therapy, 2021
The SPOP-ITCH Signaling Axis Protects Against Prostate Cancer Metastasis.
Ma J et al.
Frontiers in Oncology, 2021
Extreme value theory as a framework for understanding mutation frequency distribution in cancer genomes.
Tokutomi N et al.
Plos One, 2021